Are sodium‐glucose cotransporter‐2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with <scp><i>SLC5A2</i></scp> mutation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Are sodium‐glucose cotransporter‐2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation

Published:2024-06-26 Issue:7 Volume:16 Page:
ISSN:1753-0393
Container-title:Journal of Diabetes
language:en
Short-container-title:Journal of Diabetes

Author:

Ahangar Davoodi Mohamad¹,Daneshmand Mohammad Ali²,Rezaei Taraneh³

Affiliation:

1. Department of Pediatric Endocrinology Arak University of Medical Sciences, Clinical Research Development Center of Amirkabir Hospital Arak Iran

2. Arak University of Medical Sciences, Teacher of Pathology in Arak Medical School Arak Iran

3. Student Research Committee Arak University of Medical Sciences Arak Iran

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1753-0407.13570

Reference14 articles.

1. Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes

2. SGLT2 inhibitors and renal complications in type 1 diabetes

3. The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves β-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat

4. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus

5. SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP